OTC Firms Question Enforceability Of Proposed USP Monograph Shake-Up
This article was originally published in The Tan Sheet
Executive Summary
OTC industry executives advise U.S. Pharmacopeia to proceed cautiously with novel approaches to modernizing its monographs, lest USP develop standards unenforceable by FDA.
You may also be interested in...
USP Monograph Modernization Requires Flexibility For OTCs, Experts Agree
The U.S. Pharmacopeia monograph modernization initiative must take a flexible approach in order to accommodate formulation of complex OTC products, experts say.
NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.
NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.